{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:48:21Z","timestamp":1791499701784,"version":"4.3.4"},"reference-count":69,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Attention-deficit\/hyperactivity disorder (ADHD), the single most common neuropsychiatric disorder with cognitive and behavioral manifestations, often starts in childhood and usually persists into adolescence and adulthood. Rarely seen alone, ADHD is most commonly complicated by other neuropsychiatric disorders that must be factored into any intervention plan to optimally address ADHD symptoms. With more than 30 classical Schedule II (CII) stimulant preparations available for ADHD treatment, only three nonstimulants (atomoxetine and extended-release formulations of clonidine and guanfacine) have been approved by the United States Food and Drug Administration (FDA), all of which focus on modulating the noradrenergic system. Given the heterogeneity and complex nature of ADHD in most patients, research efforts are identifying nonstimulants which modulate pathways beyond the noradrenergic system. New ADHD medications in clinical development include monoamine reuptake inhibitors, monoamine receptor modulators, and multimodal agents that combine receptor agonist\/antagonist activity (receptor modulation) and monoamine transporter inhibition. Each of these \u201cpipeline\u201d ADHD medications has a unique chemical structure and differs in its pharmacologic profile in terms of molecular targets and mechanisms. The clinical role for each of these agents will need to be explored with regard to their potential to address the heterogeneity of individuals struggling with ADHD and ADHD-associated comorbidities. This review profiles alternatives to Schedule II (CII) stimulants that are in clinical stages of development (Phase 2 or 3). Particular attention is given to viloxazine extended-release, which has completed Phase 3 studies in children and adolescents with ADHD.<\/jats:p>","DOI":"10.1017\/s1092852920001984","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T07:10:20Z","timestamp":1604041820000},"page":"199-207","source":"Crossref","is-referenced-by-count":17,"title":["Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents"],"prefix":"10.1017","volume":"27","author":[{"given":"Andrew J.","family":"Cutler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory W.","family":"Mattingly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Welton","family":"O\u2019Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"S1092852920001984_r55","doi-asserted-by":"publisher","DOI":"10.1159\/000468422"},{"key":"S1092852920001984_r68","unstructured":"68. Supernus. A Phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group flexible-dose study of the efficacy and safety of SPN-812 in adults with attention-deficit\/hyperactivity disorder (ADHD). Accessed at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04016779. November 16, 2020."},{"key":"S1092852920001984_r62","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.05.021"},{"key":"S1092852920001984_r46","unstructured":"46. Intuniv [prescribing information]. Lexington, MA: Shire Pharmaceuticals, Inc., Revised 02\/2013. Accessed at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022037s009lbl.pdf. February 1, 2020."},{"key":"S1092852920001984_r32","unstructured":"32. Otsuka [press release].Otsuka announces positive top-line results from two Phase 3 studies of centanafadine for the treatment of attention-deficit hyperactivity disorder (ADHD) in adult patients. Accessed at: https:\/\/www.otsuka-us.com\/discover\/otsuka-announces-positive-top-line-results-from-two-phase-3-studies-of-centanafadine. February 1, 2020."},{"key":"S1092852920001984_r19","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2019.1628640"},{"key":"S1092852920001984_r2","doi-asserted-by":"publisher","DOI":"10.1080\/15374416.2017.1417860"},{"key":"S1092852920001984_r34","unstructured":"34. Otsuka. A phase 2, multicenter, randomized, double-blind, active- and placebo-controlled trial of the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit\/hyperactivity disorder. Accessed at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03324581 . February 1, 2020."},{"key":"S1092852920001984_r28","unstructured":"28. Sunovion [press release]. Sunovion announces acceptance by the U.S. FDA of the New Drug Application for dasotraline for the treatment of adults with moderate-to-severe binge eating disorder. Accessed at: https:\/\/news.sunovion.com\/press-releases\/press-releases-details\/2019\/Sunovion-Announces-Acceptance-by-the-US-FDA-of-the-New-Drug-Application-for-Dasotraline-for-the-Treatment-of-Adults-with-Moderate-to-Severe-Binge-Eating-Disorder\/default.aspx. November 16, 2020."},{"key":"S1092852920001984_r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2010.11.005"},{"key":"S1092852920001984_r39","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0336-0"},{"key":"S1092852920001984_r44","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2013.0103"},{"key":"S1092852920001984_r35","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923000-00005"},{"key":"S1092852920001984_r24","doi-asserted-by":"publisher","DOI":"10.1177\/1087054719864644"},{"key":"S1092852920001984_r25","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0083"},{"key":"S1092852920001984_r14","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181bf6303"},{"key":"S1092852920001984_r1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852916000808"},{"key":"S1092852920001984_r16","unstructured":"16. Strattera [prescribing information]. Indianopolis, IN: Eli Lilly & Co; 2017. Accessed at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021411s048lbl.pdf. February 1, 2020."},{"key":"S1092852920001984_r29","unstructured":"29. Robertson, BA , Shram, M , Schoedel, KA . Early stage assessment of the abuse potential of centanafadine, a triple reuptake inhibitor: preclinical and clinical study results. Poster presented at: 53rd Annual Meeting of the American College of Neuropsychopharmacology. 2014. Accessed at: http:\/\/www.neurovance.com\/wp-content\/uploads\/2014\/03\/Neurovance_CTN_HAL_ACNP_2014.pdf:7\u201311. February 1, 2020."},{"key":"S1092852920001984_r59","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S256586"},{"key":"S1092852920001984_r60","unstructured":"60. Johnson, JK , Saylor, K , Brittain, ST , et al. Double-blind, randomized, placebo-controlled study of immediate-release viloxazine (SPN-812 IR) as a novel non-stimulant therapy in adults with attention-deficit\/hyperactivity disorder (ADHD). Poster presented at: Annual Meeting of the American Academy of Child & Adolescent Psychiatry; October 26\u201331, 2015; San Antonio, TX."},{"key":"S1092852920001984_r6","doi-asserted-by":"publisher","DOI":"10.1037\/adb0000012"},{"key":"S1092852920001984_r22","unstructured":"22. ADIS Insight. Dasotraline - Sumitomo Dainippon Pharma. ADIS Insight. 2019;Update 07 Aug 2019. Accessed at: https:\/\/adisinsight.springer.com\/drugs\/800023450. February 1, 2020."},{"key":"S1092852920001984_r66","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13395"},{"key":"S1092852920001984_r31","unstructured":"31. Jennings, D , Barret, O , Wisniewski, G , et al. Centanafadine SR (CTN-SR) demonstrates brain occupancy at norepinephrine transporter (NET), serotonin transporter (SERT) and dopamine transporter (DAT) using single photon emission tomography (SPECT) in healthy volunteers (HVS). Poster presented at 2016 American Society of Clinical Psychopharmacology, May 30\u2013June 2, 2016; Scottsdale, AZ. Accessed at: https:\/\/ascpmeeting.org\/wp-content\/uploads\/2014\/07\/2016-Oral-Abstract-Book-FINAL-with-cover-page.pdf. February 1, 2020."},{"key":"S1092852920001984_r52","first-page":"2321","article-title":"Pilot Phase II study of mazindol in children with attention deficit\/hyperactivity disorder","volume":"8","author":"Konofal","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"S1092852920001984_r30","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S242084"},{"key":"S1092852920001984_r37","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e318197748f"},{"key":"S1092852920001984_r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.11.005"},{"key":"S1092852920001984_r41","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-3695"},{"key":"S1092852920001984_r48","unstructured":"48. Trintellix [prescribing information]. Deefield, IL: Takeda Pharmaceuticals America, Inc. Revised 07\/2019. Accessed at: https:\/\/general.takedapharm.com\/trintellixpi\/. February1, 2020."},{"key":"S1092852920001984_r61","doi-asserted-by":"publisher","DOI":"10.1177\/1087054719836159"},{"key":"S1092852920001984_r3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.9.1621"},{"key":"S1092852920001984_r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.11.009"},{"key":"S1092852920001984_r57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1974.tb00282.x"},{"key":"S1092852920001984_r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.09.369"},{"key":"S1092852920001984_r18","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113478475"},{"key":"S1092852920001984_r54","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197713060-00001"},{"key":"S1092852920001984_r7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33004-1"},{"key":"S1092852920001984_r20","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0358-7"},{"key":"S1092852920001984_r58","doi-asserted-by":"publisher","DOI":"10.1017\/S0264180100000709"},{"key":"S1092852920001984_r42","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e318191769e"},{"key":"S1092852920001984_r33","unstructured":"33. Otsuka Group. Pipeline Information. 2019. Accessed at: https:\/\/www.otsuka.com\/en\/rd\/pharmaceuticals\/pipeline\/pdf.php?financial=652. February 1, 2020."},{"key":"S1092852920001984_r47","unstructured":"47. Kapvay [prescribing information]. Atlanta, GA: Shionogi Pharma, Ltd. 2010. Accessed at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022331s001s002lbl.pdf. February 1, 2010."},{"key":"S1092852920001984_r17","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e31815d88b2"},{"key":"S1092852920001984_r53","unstructured":"53. NLS [press release]. NLS Pharmaceutics announces the completion of the merger between NLS Pharma Ltd., NLS1 Pharma Ltd. and NLS-0 Pharma, unifying the global operations and sevelopment of Nolazol. Accessed at: https:\/\/www.globenewswire.com\/news-release\/2019\/03\/19\/1757387\/0\/en\/NLS-Pharmaceutics-Announces-the-Completion-of-the-Merger-between-NLS-Pharma-Ltd-NLS-1-Pharma-Ltd-and-NLS-0-Pharma-Unifying-the-Global-Operations-and-Development-of-Nolazol.html. November 16, 2020."},{"key":"S1092852920001984_r69","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852919001822"},{"key":"S1092852920001984_r27","unstructured":"27. Sunovion [press release]. FDA issues a complete response letter for New Drug Application for dasotraline for the treatment of ADHD. Accessed at: https:\/\/news.sunovion.com\/press-releases\/press-releases-details\/2018\/FDA-Issues-a-Complete-Response-Letter-for-New-Drug-Application-for-Dasotraline-for-the-Treatment-of-ADHD\/default.aspx. November 16, 2020."},{"key":"S1092852920001984_r56","doi-asserted-by":"publisher","DOI":"10.1002\/hup.470060106"},{"key":"S1092852920001984_r5","first-page":"666","volume-title":"Attention-Deficit\/Hyperactivity Disorder: A Handbook for Diagnosis and Treatment","author":"Connor","year":"2015"},{"key":"S1092852920001984_r26","first-page":"22745","article-title":"Dasotraline for the treatment of attention deficit\/hyperactivity disorder in adults: pooled analysis of two double-blind studies","volume":"40","author":"Adler","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"S1092852920001984_r9","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(02)00346-9"},{"key":"S1092852920001984_r63","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852920000310"},{"key":"S1092852920001984_r36","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1147558"},{"key":"S1092852920001984_r13","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S115707"},{"key":"S1092852920001984_r23","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.124"},{"key":"S1092852920001984_r8","first-page":"61","article-title":"A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain","volume":"222","author":"Wong","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852920001984_r67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2020.08.092"},{"key":"S1092852920001984_r65","unstructured":"65. Supernus. Evaluation of SPN 812 ER 400 and 600 mg efficacy and safety in adolescents with ADHD - a double-blind, placebo-controlled, pivotal trial. Accessed at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03247556. November 16, 2020."},{"key":"S1092852920001984_r43","doi-asserted-by":"publisher","DOI":"10.1177\/070674371506000202"},{"key":"S1092852920001984_r64","first-page":"272","article-title":"A Phase 3, randomized, double-blind, placebo-controlled study (P302): efficacy and safety of extended-release viloxazine in adolescents with ADHD","volume":"25","author":"Nasser","year":"2020","journal-title":"CNS Spectr"},{"key":"S1092852920001984_r21","unstructured":"21. Sepracor [press release]. Sepracor provides update on clinical trials for SEP-225289 and LUNESTA\u00ae Pediatrics. Accessed at: https:\/\/wwwbusinesswirecom\/news\/home\/20090701006146\/en\/Sepracor-Update-Clinical-Trials-SEP-225289-LUNESTA\u00ae-Pediatrics. July 1, 2009."},{"key":"S1092852920001984_r51","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2004.029.12.855246"},{"key":"S1092852920001984_r10","unstructured":"10. Food & Drug Administration. Strattera Clinical Safety Review. 2002. Accessed at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-411_Strattera_medr_P3.pdf. November 16, 2020."},{"key":"S1092852920001984_r49","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119832538"},{"key":"S1092852920001984_r12","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200911030-00005"},{"key":"S1092852920001984_r15","doi-asserted-by":"publisher","DOI":"10.1521\/capn.2016.21.4.1"},{"key":"S1092852920001984_r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2012.09.008"},{"key":"S1092852920001984_r50","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0503-y"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852920001984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T02:57:14Z","timestamp":1651114634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852920001984\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1092852920001984"],"URL":"https:\/\/doi.org\/10.1017\/s1092852920001984","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]}}}